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Using a monochromator the action spectrum for ultra-
violet phototherapy of psoriasis was determined for ra-
diation between 254 and 313 nm and compared to the 
action spectrum for erythema of uninvolved adjacent 
skin. Daily exposures of different doses of 254, 280, 290, 
296, 300, 304 and 313 nm radiation were observed. Wave-
lengths of 254, 280, and 290 nm were erythemogenic but 
not therapeutic even at 10 to 50 times the minimal ery-
thema dose. At the other wavelengths studied, the 2 
action spectra were similar. In general, fixed daily doses 
cleared at lower cumulative dose than did incrementally 
increased daily doses. The small number of suberythem-
ogenic exposure doses required suggests that monochro-
matic radiation may have advantages over broadband 
sources. 
Phototherapy and heliotherapy with and without tar prod-
ucts have been standard moderately effective therapies for 
psoriasis for ma ny decades. Although several observations de-
fine its general shape, the action spectrum for the therapeutic 
effects of ultraviolet radiation (UVR) has not been precisely 
defined . When considering the spectral sensitivity of skin, com-
monly used broadband exposW'e devices can be considered 
essentially UVB (290-320 nm) soW'ces. Phototherapy, using 
these sources, improves psoriasis with exposure to erythemo-
genic doses [1-4]. High-pressure mercW'y lamps, mercW'y xenon 
sow'ces, fluorescent "sunlamps" and sunlight are all moderately 
effective if repeated erythemogenic exposure doses are used. 
Fischer [5] showed that a narrow waveband at 313 nm was 
effective in clearing small exposure s ites within plaques of 
psoriasis. Parrish [6] has shown that large doses of broadband 
UVA (60-300 J/cm2, 320-400 nm) similarly cleared small areas 
of psoriasis. 
All phototherapy of psoriasis is limited by the acute injurious 
effects of ultraviolet radiation on normal uninvolved skin. In 
order to design maximally safe and effective treatment systems 
and protocols, it is important to know the action spectrum of 
phototherapy of psoriasis and compare it with the action spec-
trum for phototoxicity of normal skin manifest by delayed 
erythema. Such a comparison is the subject of this report. 
MATERIALS AND METHODS 
Four male Caucasian volunteers with 50% or greater body involve-
ment of psoriasis were studied. An Optical Radiation Corporation V-
4500 housing with a 5000 W Xe-Hg d.c. compact arc lamp optically 
matched to a Jobin Yvon HL300 holographic grating monochromator 
was used to obtain radiation at 280 nm, 290 nm, 296 nm, 300 nm, 304 
nm, and 313 nm (6 nm half-bandwidths) . Low-pressme mercury dis-
charge lamps filtered with a cyanine periodate/ Backstrom liquid solu-
tion [7] were used to obtain 253.7 nm radiation. Irradiance measure-
ments were made with either an Eppley (Model 16170E4) or Oriel 
(Model 7102) thermopile and a Keith ley (Model 150B) microvoltmeter. 
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At least 3 irradiance measmements were taken in different areas of 
each field site to insure uniform irradiance within ± 10%. I:rradiance 
measurements were done prior to each experiment and again at its 
conclusion. Stray light was less than 10-" for both sources. 
For each wavelength used, the minimal erythema dose (MED) was 
determined on normal (uninvolved) skin adjacent to treatment sites by 
using geometric increments of 20%. Delayed erythema was read at 24 
hr after exposme, except for the 254 nm MED, which was read at 8 hr 
after exposure. Experimental irradiation sites within plaques of pso-
riasis vulgaris ranged in area from 5 cm' to 12.5 cm2. At each wavelength 
at least 9 different sites were exposed daily (6 times/ week) for 4 weeks. 
Exposure doses on 7 of these sites were 0.2, 0.4 , 0.6,0.8, 1.0, 1.5, and 2.0 
or 2.5 t imes the previolIsly determined MED. Two additional sites for 
each wavelength were irradiated initially with 1 MED then with daily 
increases in exposure dose of 10% and 20% respectively. At 254, 280 and 
290 nm, additional sites were exposed daily to greater doses up to 53 
X MED. All experimental sites were lubricated with mineral oil twice 
daily, immediately before bed and 15 min before irradiation. No other 
topical lubricants or systemic or topical medications were used during 
the comse of the study. One addit ional patient (#5) was treated for 28 
days with 10, 28 and 43 X MED at 254 nm. 
Treated sites were observed daily. The following grading was used: 
O:No change. 
SPRSlight regression-minimal but definite reduction in 
plaque induration. 
PRPlaque regression-marked improvement, consider-
able reduction in plaque induration. 
PC:Plaque clear-complete disappearance of induration in 
90% of the treated site. Reappearance of normal skin 
texture. 
Subjects #2 and #4 were skin type III, subject #1 was skin type II, and 
subject #3 was skin type I. Erythema and pigmentation within the 
treated sites were recorded on a 0-4+ scale [8]. 
RESULTS 
At 254, 280 and 290 nm no exposW'e sites showed any im-
provement at any exposure dose. At these wavelengths the 
lowest effective daily dose for complete clearing (LEDD) must 
be greater than the highest exposure dose tested in this exper-
iment because no improvement was seen even though 10 to 53 
times MED were used (see Table I). Subject #5 showed no 
response to exposmes of 10, 28 and 43 x MED at 254 nm. 
At 296 nm, results ranged from no effect to complete clearing 
depending upon daily exposme dose. In 2 subjects, repeated 
suberythemogenic exposure doses led to clearing. That is, in 
both patients #1 and #3 the LEDD was lower than the MED. 
In one subject (#4) repeated exposW'e to 1.5 times MED was 
required for complete clearing and the other subject showed 
improvement but not clearing at the highest dose used (2.5 x 
MED in subject #2). 
At both 300 and 304 nm, complete clearing occurred with 
daily exposW'es to doses equal to or less than MED in all but 
subject #2. In subject #2, the 1 X MED site at 300 nm was 
imptoved but repeated exposW'es to 2.5 X MED was required 
for complete clearing. 
In every subject, suberythemogenic exposW'e doses of 313 nm 
led to complete clearing. As little as 0.2 X MED was effective 
in subject #l. 0.4 X MED showed improvement in every subject 
but led to complete clearing only in subject #l. But because 
the MED for 313 nm radiation is more than 10 times greater 
than that for shorter wavelengths, LEDD was at least 10 times 
greater at 313 nm than LEDD at 300 or 304 nm. FW'thermore 
sites treated with 2.0 or 2.5 X MED at 313 nm or with incre~ 
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TABLE I. Comparison of Minimal Erythema Dose of Normal Shin and Lowest Effective Daily Dose to Clearing of Psoriasis" 
Pt. I Pt. 2 Pt. 3 Pt.4 
Allm mJ /cm' mJ /cm' LEDD/ mJ /cm' mJ /cm' LEDD/ mJ/cm' mJ/ cm' LEDD/ mJ/cm' mJ / cm' LEDD/ 
MED LEDD MED MED LEDD MED MED LEDD MED MED LEDD MED 
254 19.0 >1007 >53 18 >900 50 ND ND ND ND ND ND 
280 49.0 >1029 >21 49 >1225 >25 45 > 1125 >25 59 >590 >10 
290 33 >924 >28 48 >1200 >25 17 >425 >25 31 >310 >10 
296 26 21 0.8 22 >55 >2.5 17 10 0.6 26 39 1.5 
300 41 16 0.4 34 85 2.5 27 21 0.8 32 19 0.6 
304 76 30 0.4 119 72 0.6 28 28 1 62 62 1 
313 1971 400 0.2 1643 986 0.6 478 287 0.6 1100 660 0.6 
" Minimal erythema dose (MED) and lowest effective daily dose to clearing (LEDD) in 4 subjects. Doses preceded by > give the highest dose 
tested in t his experiment. Because clearing was not achieved at th is dose the actual LEDD will be greater than this dose. Suberythemogenic 
exposure doses lead to clearing if LEDD/ MED <1. 
TABLE II. Comparison of number of treatments to clear with lowest effective daily dose to clearing (LEDD) and with incrementally 
increasing doses" 
(1.I)NMED (1.2)N MED LEDD 
Subject Number 2 3 2 3 4 2 3 
>-nm 
296 10 X 15 X 10 X 14 ND 5 X 19 15 
300 5 11 20 16 5 11 21 ND 5 12 23 21 
304 7 6 17 12 7 6 17 ND 4 9 23 12 
313 7 8 18 5 7 ND ND ND 6 13 23 12 
" Number of treatments required to ach ieve complete clearing at each waveband for each of 3 daily exposure doses. MED = minimal erythema 
dose. (l.l) N MED refers to daily increase in dose by 10%, (1.2)N MED refers to daily incr emental increase of 20%, N = treatment number. 
Numbers at top of each column refer to subject number. X means that complete clearing was never achieved. ND means not done. 
TABLE III. Lowest number of treatments to clear" 
Subject I Subject 2 Subject 3 Subject 4 
Anm Treatments MED 1'reatments MED Treatments MED Treatments MED Multiple Multiple Multiple Mult iple 
296 5 0.8' > 14 >2.5 14 (1.2) N 11 2.0 
300 5 0.4 ' 11 (l.l)N 20 (1.I)N 11 2.0 
304 4 0.4' 6 1.0 17 (l.l)N 6 1.2 
313 5 1.0 7 1.0 18 (l.l) N 5 (l.l)N 
" The lowest number of treatments to clear and the exposure dose in multiples of minimal erythema dose (MED) leading to this clearing are 
listed. (1.1) N and (1.2) N refer to 10% and 20% daily increases in dose where N = treatment number. The MED multiples with asterisks are equal 
to those lowest effective daily doses which cleared psoriasis (LEDD). 
TABLE IV. Cumulative dose to clearing at lowest effective daily dose to clearing of psoriasis (LEDD) and incrementally increasing doses" 
(I.l) N (1.2)N LEDD 
mJ /cm' mJ / cm' mJ /cm' Subject # 
2 3 4 2 3 2 3 4 
>-nm 
296 740 >614 578 >1,857 1,032 1,298 1,176N 105" >7 19 " 58 " 
300 43Q 634" 1,703 1,151 459 1,098 4,152 D 80" 70 0" 5" 
304 1,258 920 1,226 1,327 1,480 1,183 3,495N 120" 1,0 " 48 " 39 " 
313 32,640 18,784 23,950 6,700" 34,521 ND NDD 2,400" 32" 3" 9 
N 64 64 74 
D 8 4 4 
N 12, 6,6 7,9 
D 81 01 20 
8 
" Cumulative dose to clearing in mJ/cm 2 at sites treated with 10% increments [(1.1)N MED], 20% increments [(1.2)N MED], and daily dose 
which proved to be lowest effective daily dose to clear psoriasis (LED D) . N = treatment number. 
" The lowest cumulative dose at each wavelength leading to clearing. In a ll but 2 cases the lowest cumulative dose to clearing occurred at fixed 
LEDD and not with incrementally increasing doses. 
mentally increasing doses showed tenderness, increase in in-
duration and scaling, and occasionally petechiae. 
At some sites complete clearing was achieved in as few as 4 
to 7 treatments (see Table II). Except for subject #1, in general, 
but not always, sites exposed to incrementally increased doses 
cleared quicker (fewer number oftreatments) than sites exposed 
repeatedly to fixed doses that later proved to be LEDD, but 
the differences were small. However, exposure doses greater 
than LEDD often led to complete clearing in even fewer treat-
ments (see Table III). 
At each wavelength causing clearing, sites exposed to fixed 
daily doses cleared with smaller cumulative dose than sites 
treated with incremental increasing doses (Table IV). The only 
exceptions were seen in subject #2 at 300 nm and in subject 
#4 at 313 nm. At 300 nm in subject #2, the site treated daily 
with 10% increase in dose had lower cumulative dose to clearing 
than was accomplished with a fixed dose at LEDD. At 313 nm 
in subject #4 10% incremental increases led to lower cumulative 
dose to clear than with the fixed dose that proved to be LEDD. 
With 2 exceptions (subject #2 at 300 nm and subject #4 at 
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TABLE V. Lowest cumulative dose to clearing" 
Anrn Dose mJ /cm' MED multiple Dose mJ/cm' MED multiple Dose mJ / cm' MED multiple Dose mJ /cm' MED multiple 
105 0.8 >770 >2.5 190 0.6 572 2.0b 296 
300 
304 
313 
80 0.4 634 (l.l) N 483 0.8 399 0.6 
120 0.4 648 0.6 644 1.0 446 1.2" 
2,400 0.2 11,501 1.0/' 6,601 0.6 6,700 (l.l)N 
a Lowest cumulative dose to clearing at each waveband. MED = Minimal erythema dose of adjacent uninvolved skin prior to any phototherapy. 
(l.l)N = Daily doses increased by 10%, N = treatment number. 
b In 3 s ites a fixed daily dose greater than lowest effective daily dose to clearing (LEDD) led to a lower cumulative dose because at the higher 
dose fewer treatments were required. 
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FlG 1. The erythema action spectrum (subject 1) (the reciprocal of 
the minimal erythema dose vs. A nm) is indicated by the line with 
squares. The phototherapy action spectrum (reciprocal of lowest effec-
tive daily dose to clearing vs. A nm) is shown by the solid line. The 
circles represent the highest doses tried on a daily basis at wavelengths 
which showed no improvement of psoriasis. The clotted line shows the 
rapid decline in therapeutic effectiveness of wavelengths less than or 
equal to 290 nm. 
313 nm), the lowest cumulative dose to clearing was achieved 
with a fIxed daily dose instead of incremental increasing doses 
(Table V). In 3 sites (footnote b in Table V) a fIxed daily dose 
greater than LEDD led to a lower cumulative dose because 
fewer treatments were required at the larger exposure dose. 
The action spectra for delayed erythema in all of the subjects 
was within normal values [8]. Fig 1 gives a typical delayed 
erythema action spectrum (subject #1) and compares this to 
the action spectrum for the complete clearing of psoriasis under 
the conditions of this study. Fig 2 compares the combined 
action spectra for delayed erythema and phototherapy in all 
subjects. 
Subsequent to this study these patients were treated with 
conventional treatments and proved to be difficult to manage. 
Two patients cleared very slowly (20 and 22 treatments) on 
protocols known to be effective [9]. One additional patient 
could not be improved at all with 14 treatments with UVB 
(FS40 bulbs) therapy. The fmal patient required both Metho-
trexate and PUV A to clear. This suggests that the fewer number 
of treatments required to clear psoriasis in small areas with 
monochromatic radiation was probably not due to patient se-
lection. 
DISCUSSION 
The action spectra for phototherapy of psoriasis and for 
delayed erythema of normal skin are quite different for wave-
lengths less than or equal to 290 nm. Radiation of wavelengths 
less than 296 are very phototoxic to normal skin as manifest by 
a low threshold for induction of delayed erythema. This radia-
tion is, however, not effective in phototherapy. Repeated daily 
exposure to as many as 50 times MED caused no gross changes 
in treated sites of psoriasis. 
The marked decrease in effectiveness of wavelengths shorter 
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FlG 2. The erythema action spectra mean (subjects 1 to 4) is indi-
cated by the line with squares. The phototherapy action spectrum 
mean is shown by the solid line. The solid circles represent each 
subject's reciprocal lowest effective daily dose to clearing. The circles 
with triangles represent means of the highest doses tried on a daily 
basis at wavelengths which showed no improvement of psoriasis. The 
dotted line shows the steep decline in therapeutic effectiveness at 
wavelengths less than or equal to 290 nm. 
than 296 nm may be explained by optical and structural differ-
ences between psoriatic and normal skin. In psoriasis the pro-
liferative compartment at the bottom of the epidermis is thicker 
and on the average is deeper within the tissue. There is also an 
increased thickness of stratum corneum and an increased scale 
with multiple air-tissue interfaces in psoriasis. Epidermal pro-
teins absorb wavelengths shorter than approximately 295 nm, 
and optical scattering also increases at shorter wavelengths. In 
general, transmission decreases exponentially with increasing 
thickness of an optical baJTier. Transmission of radiation 
shorter than 290 nm to the proliferating epidermal cells in 
psoriasis may therefore be markedly reduced compared with 
that for normal skin. Considering thickness alone, a 4-fold 
increase in stratum corneum thickness over that of normal skin 
(8 to 10 /Lm) could decrease transmission of radiation at 280 nm 
by a factor of 104 or more. Other explanations for the ineffec-
tiveness of shorter wavelengths are possible. Phototherapy and 
ul traviolet induced inflammation may involve entirely different 
chromophores. Competitive waveband interaction may occur 
with broadband sources with shorter wavelengths having a net 
proliferogenic stimulus. 
In the region of 296-313 nm the action spectrum for photo-
therapy appears to be similar to that for delayed erythema. At 
296, 300 and 304 nm the exposw-e dose required to induce 
delayed erythema is similar to the daily dose required to clear 
psoriasis from small sites within psoriatic plaques. 
Previous studies suggest that the action spectra for delayed 
erythema of normal skin and for therapy of psoriasis may also 
be closely aligned in the UV A region. UV A is markedly less 
erythemogenic t han is UVB, requiring as much as 1000 times 
greater doses [6]. Young and van der Leun [10] found that 14 
daily exposures to 7-14 J/cm2 of UVA had no effect on psoriasis. 
No erythema was reported to occur on normal skin. Fischer [5] 
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found 30 J/cm2 of primarily 365 run radiation to be ineffective 
in most test sites. Normal skin was not irradiated but this dose 
may be minimally erythemogenic to some, but not all, light 
Caucasians. Pan'ish [6], using larger exposure doses of 50 to 300 
J / cm2, found broadband UVA (320-400 nm) to be effective in 
clearing psoriasis fTom small exposure sites. Comparative stud-
ies showed these doses of UV A to be as effective as doses of 
UVB 1000 times less. The UV A MED with the same exposure 
sources was 20 to 100 J/cm2 . 
The results of this study suggest that eliminating radiation of 
wavelengths less than 296 nm, which are erythemogenic but 
apparently not phototherapeutic, may improve the efficacy of 
phototherapy. This may in part explain the effectiveness of so-
called selective ultraviolet phototherapy [11-13] which has 
peak emission at 300 to 325 run and heliotherapy at the Dead 
Sea where increased solar ultraviolet pathlengths may decrease 
photon flux 'of shorter wavelength ultraviolet radiation [14]. 
This work also suggests that monochromatic radiation may be 
more therapeutic than exposures to broadband sources. The 
number of treatments and cumulative dose to clearing was 
considerably less than required with conventional UVB sources 
[9, 15]. This difference may be related to the small experimental 
sites employed, but this appears unlikely. At the end of this 
study, 2 patients were treated with total body UVB using 
fluorescent FS40 Westinghouse bulbs, which have a broad 
emission spectrum including wavelengths as short as 275 nm, 
and it was found that within 7 days psoriasis selectively re-
turned to sites previously exposed and cleared using the mon-
ochromatic source at 300, 304, 313 nm. This suggests that 
broadband sources may not be unnecessarily erythemogenic 
but may contain nontherapeutic, proliferogenic components. 
We are most grateful to the patients who volunteered as subjects for 
this long and tedious experiment. We are also grateful to Mr. R. Rox 
Vol. 76, No.5 
Anderson for his expertise and to Nolan Kagetsu for his technical 
assistance. 
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